NeuroPace Cuts Full-Year Guidance After Q3 Revenue Miss
As seen on the 24/7 Wall St. homepage on November 12, 2026.
NeuroPace cut full-year revenue guidance to $91 million to $92 million from $99.5 million to $101.5 million after a shortfall concentrated in a few of its largest accounts and a disruptive field sales reorganization. Management says fourth-quarter scheduled cases are already recovering, but the credibility damage lands first.
Continue ReadingShow less
NeuroPace reported Q3 2026 revenue of $23.1 million, missing the consensus estimate of $27.2 million. Management traced the shortfall to disruptions in several of its largest accounts and to a field sales reorganization.
The more consequential number for investors is the full-year outlook: management cut 2026 revenue guidance to $91 million to $92 million from a prior $99.5 million to $101.5 million. Adjusted EBITDA guidance widened to a larger loss as well.
CEO Joel Becker said the shortfall was isolated to account-level issues and field-organization changes, and that fourth-quarter scheduled cases have already begun to recover. The company raised non-GAAP gross margin guidance and trimmed operating expense expectations, but those offsets do not close the gap left by the revenue cut.
Sponsored
Beyond the commercial stumble, regulatory milestones will shape the stock's trajectory: NeuroPace expects to file its IGE indication PMA supplement amendment around year end after an October FDA meeting. It has also submitted NeuroPace Remote Care for FDA review and begun enrolling patients in the AURORA study.
The EPS history heading into this report had shown a consistent pattern of beating lowered estimates, and Q3 2026 broke that streak on both lines. With cash and equivalents at $10.2 million against long-term debt of $59.2 million, the balance sheet leaves little room for further commercial execution slippage.
Mentioned: NPCE